The survival benefit of radiotherapy in localized primary adult rhabdomyosarcoma.
distant metastasis
local recurrence
overall survival
radiotherapy
rhabdomyosarcoma
Journal
Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
07
09
2018
accepted:
09
02
2020
pubmed:
15
4
2020
medline:
15
9
2020
entrez:
15
4
2020
Statut:
ppublish
Résumé
To evaluate the role of radiotherapy (RT) in the treatment of localized primary adult rhabdomyosarcoma (RMS). This retrospective study identified 62 consecutive adult patients with localized primary RMS from January 2000 and July 2016. Local failure-free survival (LFFS), distant metastasis-free survival (DMFS) and overall survival (OS) were analyzed by the Kaplan-Meier method. Multivariate Cox proportional hazards regression models were fit to assess the ability of patient characteristics to predict survival. With a median follow-up of 33 months (range, 6-195 months), the 5-year LFFS, DMFS and OS of all patients were 64.0%, 50.0% and 45.0%, respectively. RT was administered to 28 patients (45.2%). Patients who received RT had a higher 5-year LFFS (81.7% vs 47.2%), 5-year DMFS (59.4% vs 43.1%) and 5-year OS (57.1% vs 34.8%) compared with patients who did not received RT. In mulitvariate analysis, RT retained significance as an independent predictor of improved LFFS [hazard ratio (HR) = 0.282; 95% confidence interval (CI), 0.095-0.838; P = 0.023], DMFS (HR = 0.289; 95% CI, 0.125-0.991; P = 0.004) and OS (HR = 0.334; 95% CI, 0.153-0.727; P = 0.006). RT significantly reduced local recurrence, distant metastasis and tumor mortality compared with no radiotherapy for localized primary adult RMS.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
266-272Subventions
Organisme : Zhejiang Medical and Health Science and Technology Program
ID : 2017171226
Organisme : Hangzhou Health and Family Planning Technology Project
ID : 2018A31
Informations de copyright
© 2020 John Wiley & Sons Australia, Ltd.
Références
Ruiz-Mesa C, Goldberg JM, Coronado Munoz AJ, et al. Rhabdomyosarcoma in adults: New perspectives on therapy. Curr Treat Options Oncol. 2015;16(6):27.
Sultan I, Qaddoumi I, Yaser S, et al. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: An analysis of 2,600 patients. J Clin Oncol. 2009;27(20):3391-3397.
Van Gaal JC, De Bont ES, Kaal SE, et al. Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: the road ahead. Crit Rev Oncol Hematol. 2012;82(3):259-279.
Dumont SN, Araujo DM, Munsell MF, et al. Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients. Cancer Med. 2013;2(4):553-563.
Ferrari A, Dileo P, Casanova M, et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer. 2003;98(3):571-580.
Raney RB, Maurer HM, Anderson JR, et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma. 2001;5(1):9-15.
Stock N, Chibon F, Binh MB, et al. Adult-type rhabdomyosarcoma: analysis of 57 cases with clinicopathologic description, identification of 3 morphologic patterns and prognosis. Am J Surg Pathol. 2009;33(12):1850-1859.
Hawkins WG, Hoos A, Antonescu CR, et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer. 2001;91(4):794-803.
Furlong MA, Mentzel T, Fanburg-Smith JC. Pleomorphic rhabdomyosarcoma in adults: A clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers. Mod Pathol. 2001;14(6):595-603.
Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J Clin Oncol. 2001;19(12):3091-3102.
Dasgupta R, Fuchs J. Rodeberg D: Rhabdomyosarcoma. Semin Pediatr Surg. 2016;25(5):276-283.
Folkert MR, Singer S, Brennan MF, et al. Comparison of local recurrence with conventional and intensity-modulated radiation therapy for primary soft-tissue sarcomas of the extremity. J Clin Oncol. 2014;32(29):3236-3241.
Ludmir EB, Paulino AC, Grosshans DR, et al. Regional nodal control for head and neck alveolar rhabdomyosarcoma. Int J Radiat Oncol Biol Phy. 2018;101(1):169-176.
Esnaola NF, Rubin BP, Baldini EH, et al. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg. 2001;234(2):215-223.
Hayashi Y, Ohi R, Okabe I, et al. [TNM classification-pediatric tumors]. Gan To Kagaku Ryoho. 1998;25(3):431-441.
Maurer HM, Beltangady M, Gehan EA, et al. The intergroup rhabdomyosarcoma study-I. A final report. Cancer. 1988;61(2):209-220.
Anderson JR, Cain KC, Gelber RD. Analysis of Survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008;26(24):3913-3915.
Noujaim J, Thway K, Jones RL, et al. Adult pleomorphic rhabdomyosarcoma: A multicentre retrospective study. Anticancer Res. 2015;35(11):6213-6217.
Gerber NK, Wexler LH, Singer S, et al. Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols. Int J Radiat Oncol Biol Phys. 2013;86(1):58-63.
Wolden SL, Anderson JR, Crist WM, et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III. J Clin Oncol. 1999;17(11):3468-3475.
Shen W, Sakamoto N, Yang L. Model to predict the survival benefit of radiation for patients with rhabdomyosarcoma after surgery: A population-based study. Int J Oncol. 2014;45(2):549-557.
Koscielniak E, Harms D, Henze G, et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: A final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol. 1999;17(12):3706-3719.
Stevens MC, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: Third study of the International Society of Paediatric Oncology-SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol. 2005;23(12):2618-2628.
Sultan I, Ferrari A. Selecting multimodal therapy for rhabdomyosarcoma. Expert Rev Anticancer Ther. 2010;10(8):1285-1301.
Defachelles AS, Rey A, Oberlin O, et al. Treatment of nonmetastatic cranial parameningeal rhabdomyosarcoma in children younger than 3 years old: Results from International Society of Pediatric Oncology Studies MMT 89 and 95. J Clin Oncol. 2009;27(8):1310.
Ladra MM, Szymonifka JD, Mahajan A, et al. Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma. J Clin Oncol. 2014;32(33):3762-3770.
Lin C, Donaldson SS, Meza JL, et al. Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803-A report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2012;82(5):1764-1770.
Zhao RP, Yu XL, Zhang Z, et al. The efficacy of postoperative radiotherapy in localized primary soft tissue sarcoma treated with conservative surgery. Radiat Oncol. 2016;11:25.
Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med. 2006;130(10):1454-1465.
Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803. J Clin Oncol. 2009;27(31):5182-5188.
Oberlin O, Rey A, Sanchez de Toledo J, et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: Long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol. 2012;30(20):2457-2465.
Little DJ, Ballo MT, Zagars GK, et al. Adult rhabdomyosarcoma: Outcome following multimodality treatment. Cancer. 2002;95(2):377-388.